Medtronic shares climb as investors digest legal overhang relief and fresh cardiac-tech updates

Medtronic plc (MDT) is up 3.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to improving sentiment after a long-running legal matter was dismissed, reducing perceived headline risk. Separately, recent clinical and regulatory updates in cardiac rhythm management may be reinforcing a “pipeline/launch momentum” narrative ahead of the company’s next scheduled earnings date.

Details:

A joint stipulation of dismissal was filed to end a years-long False Claims Act case involving allegations of kickback-tainted device claims; the settlement terms were not disclosed, but the dismissal can be read as removing an uncertainty overhang.

Recent conference-season updates highlighted new data for Medtronic’s cardiac arrhythmia portfolio, which could be supporting expectations for broader adoption of newer ablation technologies.

Medtronic has also been active on the regulatory front across product lines, including FDA-related submissions/clearances in diabetes and other device categories, which can contribute to incremental optimism around upcoming product cycles.

This could also be a positioning move ahead of Medtronic’s next scheduled results (May 20, 2026), with traders reacting to a cluster of recent “good-news” items rather than a single, definitive catalyst.

Sources:

Bloomberg Law, Medtronic (Newsroom/Press Releases), Medical Device Network

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MDT Insider Trading Activity

$MDT insiders have traded $MDT stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.

Here’s a breakdown of recent trading of $MDT stock by insiders over the last 6 months:

HARRY SKIP KIIL (EVP & President Cardiovascular) has made 0 purchases and 5 sales selling 52,524 shares for an estimated $5,132,217.
GREGORY L SMITH (EVP Global Ops & Supply Chain) has made 0 purchases and 7 sales selling 30,000 shares for an estimated $3,058,451.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$MDT Hedge Fund Activity

We have seen 1,029 institutional investors add shares of $MDT stock to their portfolio, and 1,104 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 25,623,311 shares (-74.2%) from their portfolio in Q4 2025, for an estimated $2,461,375,254
WCM INVESTMENT MANAGEMENT, LLC added 11,265,714 shares (+inf%) to their portfolio in Q1 2026, for an estimated $976,174,118
BARCLAYS PLC removed 4,590,239 shares (-67.2%) from their portfolio in Q4 2025, for an estimated $440,938,358
CAPITAL RESEARCH GLOBAL INVESTORS added 3,880,174 shares (+12.6%) to their portfolio in Q4 2025, for an estimated $372,729,514
BANK OF NEW YORK MELLON CORP removed 3,609,206 shares (-18.9%) from their portfolio in Q1 2026, for an estimated $312,737,699
WELLINGTON MANAGEMENT GROUP LLP added 3,169,781 shares (+31.1%) to their portfolio in Q4 2025, for an estimated $304,489,162
LAZARD ASSET MANAGEMENT LLC removed 2,589,540 shares (-43.1%) from their portfolio in Q4 2025, for an estimated $248,751,212

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MDT Congressional Stock Trading

Members of Congress have traded $MDT stock 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $MDT stock by members of Congress over the last 6 months:

REPRESENTATIVE KEVIN HERN sold up to $50,000 on 03/20.
REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$MDT Analyst Ratings

Wall Street analysts have issued reports on $MDT in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 02/17/2026
Barclays issued a "Overweight" rating on 01/08/2026
William Blair issued a "Outperform" rating on 01/06/2026
Wells Fargo issued a "Overweight" rating on 11/19/2025
RBC Capital issued a "Outperform" rating on 11/19/2025
Morgan Stanley issued a "Overweight" rating on 11/19/2025

To track analyst ratings and price targets for $MDT, check out Quiver Quantitative's $MDT forecast page.

$MDT Price Targets

Multiple analysts have issued price targets for $MDT recently. We have seen 17 analysts offer price targets for $MDT in the last 6 months, with a median target of $111.0.

Here are some recent targets:

Priya Sachdeva from UBS set a target price of $90.0 on 04/22/2026
Richard Newitter from Truist Securities set a target price of $95.0 on 04/15/2026
Anthony Petrone from Mizuho set a target price of $120.0 on 04/13/2026
Vijay Kumar from Evercore ISI Group set a target price of $106.0 on 04/09/2026
Joanne Wuensch from Citigroup set a target price of $110.0 on 04/07/2026
David Toung from Argus Research set a target price of $115.0 on 04/06/2026
Matt O'Brien from Piper Sandler set a target price of $91.0 on 04/01/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.